Cargando…

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation

Although autologous stem cell transplantation (auto-HCT) is the standard of care for patients with refractory/relapsed (R/R) classical Hodgkin’s lymphoma (cHL), there is still a significant proportion of patients that relapse after the procedure. This review contemplates different treatment strategi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domingo-Domènech, Eva, Sureda, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290321/ https://www.ncbi.nlm.nih.gov/pubmed/32397141 http://dx.doi.org/10.3390/jcm9051384

Ejemplares similares

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
por: Castagna, Luca, et al.
Publicado: (2015)

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2019)

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy
por: Velasco, Roser, et al.
Publicado: (2021)

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation
por: Radford, J, et al.
Publicado: (2017)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience
por: Wali, Rabia, et al.
Publicado: (2019)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation
por: Currin, Erin-Siobhain R., et al.
Publicado: (2012)

Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma
por: Wilke, Christopher, et al.
Publicado: (2017)

Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
por: Cortez, Afonso José Pereira, et al.
Publicado: (2011)

Role of Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma
por: Carella, Angelo Michele
Publicado: (2012)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
por: Zhang, Chen, et al.
Publicado: (2023)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
por: Samara, Yazeed, et al.
Publicado: (2022)

Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma
por: Fukui, Yuta, et al.
Publicado: (2022)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
por: Klyuchnikov, Evgeny, et al.
Publicado: (2011)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
por: Eskian, Mahsa, et al.
Publicado: (2018)

Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis
por: Adams, Hugo J. A., et al.
Publicado: (2016)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature
por: Boltezar, Lucka, et al.
Publicado: (2016)

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
por: Martino, R, et al.
Publicado: (1998)

Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
por: Ishizawa, Kenichi, et al.
Publicado: (2019)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study
por: De Filippi, Rosaria, et al.
Publicado: (2022)

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023)

Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience
por: Wu, Aaron, et al.
Publicado: (2020)

Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation
por: Jung, Hye Ryun, et al.
Publicado: (2011)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

P1367: COMPARISON CONDITIONING REGIMENS (BEEAC,LEAM,CLV) BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS HODGKIN’S LYMPHOMA
por: Samoylova, A., et al.
Publicado: (2022)

Autologous Stem Cell Transplantation for Aggressive Lymphomas
por: Visani, Giuseppe, et al.
Publicado: (2012)

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
por: Al-Juhaishi, Taha, et al.
Publicado: (2022)

Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile
por: Ramirez, Pablo, et al.
Publicado: (2015)

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
por: Wang, Jianhong, et al.
Publicado: (2020)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
por: Husi, Kata, et al.
Publicado: (2023)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos, Theodoros, et al.
Publicado: (2017)

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma
por: Gunnellini, Marco, et al.
Publicado: (2012)

PB2415: THE ROLE OF NUTRITIONAL SUPPORT DURING AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOHSCT) IN PATIENTS WITH HODGKIN LYMPHOMA.
por: Volchenkov, Stanislav, et al.
Publicado: (2023)

PB2435: ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN HODGKIN LYMPHOMA: A PROGNOSTIC STUDY OF 30 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
por: Zamani, Shayan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tp8e05pg5g8agderpaeqjddirc